 
 
 
Protocol: I5Q -MC -CGBC (a)  
 
 
A Phase [ADDRESS_276206].  
 
 
[STUDY_ID_REMOVED] 
 
 
Approval Date: 19-May -2020 
I5Q-MC-CGBC(a) Clinical Protocol Page 1
galcanezumab (LY2951742)Protocol I5Q-MC-CGBC
A Phase [ADDRESS_276207]
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_57957] d in the clinical investigation of 
galcanezumab ,unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries .
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commerci ally confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemptio n4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
galcanezumab -gnlm (LY2951742)
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_229490] 15 November 2019
Amendm ent (a) Electronically Signed and Approved by [CONTACT_57968].
Approval Date: 19-May-2020 GMT
I5Q-MC-CGBC(a) Clinical Protocol Page 2
galcanezumab (LY2951742)Table of Contents
Section Page
Protocol  I5Q-MC-CGBC A Phase [ADDRESS_276208] ivities....................................................................................................... 12
3. Introduction ...................................................................................................................... 15
3.1. Study  Rati onale ............................................................................................................ 15
3.2. Background .................................................................................................................. 15
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_276209] ions.................................................................................................... 26
6.4. Screen Failures ............................................................................................................. 26
7. Treatment s........................................................................................................................ 27
7.1. Treatments Administered ............................................................................................. 27
7.1.1. Packaging and Labeling ....................................................................................... 27
7.1.2. Medical Devices ................................................................................................... 27
7.2. Method of Treatment Assignment ................................................................................ 28
7.2.1. Selection and Timing o f Doses ............................................................................. 28
7.3. Blinding ....................................................................................................................... 28
7.4. Dosage Modifica tion.................................................................................................... 28
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 28
7.6. Treatment Compliance .................................................................................................29
7.7. Concomitant Therapy ................................................................................................... 29
7.8. Treatment after the End of the Study ............................................................................ 29
I5Q-MC-CGBC(a) Clinical Protocol Page 3
galcanezumab (LY2951742)8. Discontinuati on Cri teria .................................................................................................... [ADDRESS_276210] to Follow -Up........................................................................................................ 31
9. Study  Assessments and Procedures ................................................................................... 32
9.1. Efficacy Assessments ................................................................................................... 32
9.1.1. Primary Assessment of GI Transit Time ............................................................... 32
9.1.2. Secondary  Assessment Scales .............................................................................. 32
9.1.3. Appropriateness of Assessments .......................................................................... 32
9.2. Adverse Events ............................................................................................................ 32
9.2.1. Serious Adverse Events ........................................................................................ 33
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 34
9.2.2. Com plaint Handling ............................................................................................. 35
9.3. Treatment of Overdose .................................................................................................35
9.4. Safety........................................................................................................................... 35
9.4.1. Vital Signs ........................................................................................................... 35
9.4.2. Laboratory  Tests .................................................................................................. 35
9.4.3. Immunogenicit y Assessments .............................................................................. 35
9.4.4. Safety Moni toring ................................................................................................ 35
[IP_ADDRESS]. Hepati c Safet y Moni toring .............................................................................. [ADDRESS_276211] ical Considerat ions........................................................................ 37
10.3.2. Treatment Group Comparabilit y........................................................................... 38
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 38
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 38
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 38
[IP_ADDRESS]. Treatment Compliance .................................................................................... 38
I5Q-MC-CGBC(a) Clinical Protocol Page 4
galcanezumab (LY2951742)10.3.3. Efficacy Analyses ................................................................................................ 38
[IP_ADDRESS] .Primary Analyses ........................................................................................... 38
[IP_ADDRESS]. Secondary  Analyses ........................................................................................ 38
[IP_ADDRESS]. Terti ary/Exploratory  Analyses ........................................................................ 39
10.3.4. Safety Analyses .................................................................................................... 39
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 39
10.3.6. Evaluat ion of Immunogenicit y............................................................................. 40
10.3.7. Other Analyses ..................................................................................................... 40
[IP_ADDRESS]. Health Economics ........................................................................................... 40
[IP_ADDRESS]. Subgroup Analyses ......................................................................................... 40
10.3.8. Interim Analyses .................................................................................................. 40
11. References ........................................................................................................................ 41
12. Appendices ....................................................................................................................... 44
I5Q-MC-CGBC(a) Clinical Protocol Page 5
galcanezumab (LY2951742)List of Tables
Table Page
Table CGBC.2.1. Schedule of Act ivities.................................................................................... [ADDRESS_276212] ives and Endpo ints............................................................................... 19
Table CGBC.7.1. Treatment Regimens ...................................................................................... 27
I5Q-MC-CGBC(a) Clinical Protocol Page 6
galcanezumab (LY2951742)List of Figures
Figure Page
Figure CGBC.3.1. Mechanism of act ion of CGRP mo noclonal  antibodies. ............................... 17
Figure CGBC.5.1. Illustrati on of  study  design for Clinical Protocol I5Q -MC-CGBC. ............... 21
I5Q-MC-CGBC(a) Clinical Protocol Page 7
galcanezumab (LY2951742)List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 45
Appendix 2. Study  Governance Considerat ions.................................................................. 48
Appendix 3. Protocol  Amendment
I5Q-MC-CGBC(a) Summary
A Phase [ADDRESS_276213] ........................................................................................ 53
I5Q-MC-CGBC(a) Clinical Protocol Page 8
galcanezumab (LY2951742)1.Synopsis
Title of Study:
A Phase [ADDRESS_276214] .
Rationale:
Differences have been observed between reported frequencies of consti pation in clinical  trials
and postm arket ing adverse event (AE) reporting amo ng calcitonin gene -related pepti de (CGRP) 
antagonist s. In particular ,these differences have been observed between CGRP monoclonal  
antibodies(mAb)that target the ligand (galcanezumab, fremanezumab) or the receptor 
(erenumab) for the prevent ion of migraine ( Stauffer et al . 2018b; Ashina et al. 2019; FDA
[WWW] 2019; Robbins 2019; Silberstein et al. 2019
; Aimo vigpackage insert, 2020).  
Preclinical animal studies suggest thatdifferences in the mechanism o f action of  these agents 
may contribute to the different frequencies of consti pation (Hargreaves and Olesen 2019).  The 
purpose of Study  I5Q-MC-CGBC (CGBC) is to measure gastrointest inal ( GI)transit time in 
adult pati ents wi th migraine who have been initiated on prevent ive treatment with a CGRP 
antagonist (galcanezumab or erenumab), and e xplore whether there is a mechanist ic difference 
thatcontributes to GI AEs in humans.
A wireless m otility capsule (WMC )techno logywill be used to evaluate total GI transit time as 
well as segmental transit time . The US Food and Drug Administration has a pproved the WMC 
(SmartPi[INVESTIGATOR_4382]™ ) for the evaluat ion of adult patients wit h suspected delayed gastric empt ying and 
the evaluat ion of co lonic transit time (CTT) and combined small and large bowel transit time 
(SLBTT) i n pat ientswith chronic const ipation (Saad and Hasler 2011; Medtroni c 2017 ).
Com ponents to the WMC system include a WMC (SmartPi[INVESTIGATOR_4382] ™Motilit y Capsule), a wearable 
data recorder (SmartPi[INVESTIGATOR_4382] ™Motili ty Recorder), and a software program (MotiliGI™). The 
system  measures whol e gut and regional (stom ach, small bowel , and col on) transi t time by 
[CONTACT_229491], pH ,and temperature throughout the GI tract (Medtronic 2017 ). The 
American and European Neuroga stroenter ology and Motilit y Soci eties recognize dtheWMC 
techno logy as a validated, standardized, ob jective measure of GI transit time and reco mmended 
its use for testing in individuals with suspected alterations of GI motilit y (Rao et al. 2011).
I5Q-MC-CGBC(a) Clinical Protocol Page 9
galcanezumab (LY2951742)Objectives/Endp oints:
Objectives Endpoints
Primary Objective
To evaluate colonic transit time (CTT) in patients 
with migraine 1week prior to and 2weeks after
administration of an initial loading dose of 
galcanezumab 240 mg or erenumab 140 mg.Change f rom baseline inCTT after administration of 
galcanezumab or erenumab within each treatment group in 
hours at the end of Week 2.
Secondary Objectives
To evaluate transit time of the following segments 
of the gastrointestinal ( GI)tract 1week prior to and 
2weeks after administration of galcanezumab or 
erenumab:
whole gut
gastric emptying
small bowel
combined small and large bowel .Change f rom baseline in GI transit time in each of the 
following segments after administration of galcanezumab 
or erenumab within each treatment group at the end of 
Week 2:
Whole gut transit time (WGTT) in hours
Gastric emptying time (GET) ,in hours
Small bowel transit time (SBTT) ,in hours
C
ombined small and large bowel transit time 
(SLBTT) ,in hours.
To evaluate the frequency of contractions, motility 
index ,and area under the pressure curve (AUC) by 
[CONTACT_229492] .Changes in pressure parameters from baseline :
Contraction Freq/Min
Motility  Index =  ln (# of contractions x 
∑pressure amplitudes +1)  
Area under the Pressure Curve .
To evaluate number of weekly spontaneous bowel 
movements (un -aided by [CONTACT_223687], enemas, or 
suppositories) prior to and after administration of 
galcanezumab or erenumab.Change f rom baseline in number of weekly spontaneous 
bowel movements after administrat ion of galcanezumab or 
erenumab within each treatment group at Weeks 2 and 4.
To evaluate GIsymptom rating scale (GSRS) prior 
to and after administration of galcanezumab or 
erenumab.Change f rom baseline in GSRS after administration of 
galcanezumab or er enumab within each treatment group at 
Weeks 2 and 4.
To evaluate the Bristol stool form scale (BSFS)
prior to and after administration of galcanezumab or 
erenumab .Change f rom baseline in BSFS after administration of 
galcanezumab or erenumab within each t reatment group at 
Weeks 2 and 4.
Tertiary /Exploratory Objectives
To evaluate the transit time between galcanezumab 
and erenumab for
whole gut
gastric emptying
small bowel
colon
combined small and large bowel.Change f rom baseline in transit time after administration 
of galcanezumab orerenumab between treatment group sat 
the end of Week 2 for
WGTT ,in hours
GET ,in hours
SBTT ,in hours
CTT ,in hours
combined SLBTT ,in hours .
To evaluate number of weekly spontaneous bowel 
movements (un -aided by [CONTACT_223687], enemas, or 
suppositories) prior to and after administration of 
galcanezumab or erenumab.Change f rom baseline in number of weekly spontaneous 
bowel movements after administrat ion of galcanezumab or 
erenumab between each treatment group at Weeks 2 and 4.
I5Q-MC-CGBC(a) Clinical Protocol Page 10
galcanezumab (LY2951742)Objectives Endpoints
To evaluate GSRS prior to and after administration 
of galcanezumab or erenumab.Mean change difference from baseline in GSRS scores
after administration of galcanezumab or erenumab
between treatment groups at Weeks [ADDRESS_276215] -
treatment .
Summary of Study Design:
Study  CGBC is a mult icenter, randomized, single- blind study  with 2 study  periods in pat ients 
with migraine deemed eligible for prevent ive treatment by [CONTACT_229493]. Within the 2 
study  periods, there are a total of 5onsite pati ent visit s:
Visit Description
Visit [ADDRESS_276216] WMC administration and lead -in
Visit 3 Randomization and d osing
Visit 4 Second WMC administration
Visit 5 Exit visit
Treatment Arms and Duration:
Two treatm ent arms: galcanezumab (240- mg loading dose) and erenumab [ADDRESS_276217] ionnaires if the patients are deemed eligible . At Visit 2, 
administration of the WMC will occur.  At Visit 3,patients will be rando mized 1:1 t o receive 
single
-blind galcanezumab (240 -mg loading dose) or erenumab 140 mg,which will be 
administered by  [CONTACT_229494]. At Visit 4, approximately 14 days fo llowing study  treatm ent
administration (Visit 3), patients will be administered their secon d WMC upon return to site.  
Patientswill return to the study  site approximately 14days following ingest ion ofthe second
WMC for Visit 5exit visit.
Number of Patients:
The study  will screen an est imated 75potential study participants to ensure randomization of 
approximately  60 eligible patients.
Statistical Analysis:
Unless otherwise specified, analyses will be conducted on an intent -to-treat (ITT) populat ion, 
which include all patients who are randomized and receive at least 1dose of study  treatm ent.
Patients in the ITT populat ion will be analyzed according to the treatment group to which they 
are randomized. When change fro m baseline is assessed, the patient will be included in the 
analysis only if the pat ient has baseline and postbaseline measurement s.
I5Q-MC-CGBC(a) Clinical Protocol Page 11
galcanezumab (LY2951742)The primary  analysis will evaluate the changes in CTT between pre -and post -drug 
administration within each treatment group .  The primary analysis will be performed using an 
analysis of covariance (ANCOVA) model. The analysis will include the categorical effects of 
treatm ent and all rando mizat ion stratification factors, as well as the continuous baseline CTT .
Least squares mean (LSMean) change fro m baseline in each treatment group will be tested to 
detect any  change in CTT between pre -and post -drug administration.
I5Q-MC-CGBC(a) Clinical Protocol Page 12
galcanezumab (LY2951742)2.Schedule of A ctivities
I5Q-MC-CGBC(a) Clinical Protocol Page 13
galcanezumab (LY2951742)TableCGBC .2.1. Schedule of A ctivities
Study PeriodSP I
Screening and 
Baseline GI 
Transit TimeSP II
Single -Blind Treatment and Post 
WMC EvaluationNotes
Visit V1 V2 V3 V4 V5
Day -8 ± 2 -7 ± 2 0 14 ± 3 28 ± 3
Patient education regarding WMC X
Calibrate Medtronic WMC X X
WMC administration XaXFasting is defined as no food or drink, except 
water, for at least 8 hours prior to testing .
No alcohol consumption for 24 hours prior to 
ingesting the WMC and 6 hours after ingestion .
Tobacco use should also be avoided for 8 hours 
before ingestion and 6 ho urs after ingestion of 
the WMC .
Patients will consume a SmartBar immediately 
before ingesting WMC and will fast for 6 hours 
following WMC ingestion .
Patien ts should not sleep for 6 hours after 
ingesting the WMC .
Assessment that WMC has been 
expelledXbXbThe recorder will be returned to the site and data will be 
uploaded and evaluated to confirm WMC expulsion at 
Visit 3 and between Visit s4 and 5.
Study treatment administered X
Procedures
Informed consent X
Inclusion and exclusion criteria X
Concomitant medication review X X X X X
I5Q-MC-CGBC(a) Clinical Protocol Page 14
galcanezumab (LY2951742)Study PeriodSP I
Screening and 
Baseline GI 
Transit TimeSP II
Single -Blind Treatment and Post 
WMC EvaluationNotes
Visit V1 V2 V3 V4 V5
Urine pregnancy test, performed 
locallyX X
Eligible patient randomized via 
IWRSX
Physical examination X
Height X
Weight X
Medical history X
Substance use X X X Substances:  alcohol, caffeine, nicotine, tobacco .
Vital signsX X X XIncludes body temperature, sitting blood pressure, and 
pulse.
Assessment of migraine and 
headache daysXWill be done retrospectively for the previous month.
GI Symptom Rating Scale (GSRS) X X X X
Bristol Stool Form Scale X X X X
Spontaneous Bowel movement 
(SBM) frequency  evaluationX X X X
Adverse events X X X X X
Abbreviations:  GI = gastrointestinal; IBS = i rritable bowel syndrome ; IWRS = interactive web -response sy stem ;SP = stud y period; TT = transit time; V = visit; 
WMC = wireless motility capsule .
aIf the patient meets the requirement of fasting at Visit 1, then Visit [ADDRESS_276218] prior to signing the 
ICF
bAn x -ray may  be obtained in the event that the expulsion of the WMC cannot be confirmed.
I5Q-MC-CGBC(a) Clinical Protocol Page 15
galcanezumab (LY2951742)3.Introduction
3.1. Study Rationale
Differences have been observed between reported frequencies of consti pation in clinical  trials
and postm arket ing adverse event (AE) reporting amongcalcitonin gene -related pepti de (CGRP) 
antagonist s.In particular ,thesedifferences have been observed between CGRP monoclonal  
antibodies(mAb) that target the ligand ( galcanezumab, fremanezumab ) or the receptor 
(erenumab) for the prevent ion of migraine (Stauffer et al . 2018b; Ashina et al. 2019; Robbins 
2019; Silberstein et al. 2019 ; Aimo vig package insert, 2020 ).  Preclinical animal studies suggest 
that the different m echanism sof action of these agents may contribute to the different 
frequencies of consti pation(Hargreaves and Olesen 2019) . The purpose of Study  I5Q-MC-
CGBC (CGBC) is to measure gastrointestinal ( GI)transi t time in adult pat ients with migraine
who have been initiated on prevent ive treatment wit h a CGRP antagonist (galcanezumab or 
erenumab) ,and explore whether there is a mechanistic difference thatcontributes to GI AEs in 
humans.
Medtroni c’s wireless m otility capsule (WMC) techno logy, which is commercially available , will  
be used to evaluate total  GI transit time as well as segmental transit time . The Medtronic WMC
techno logy includes a WMC ( SmartPi[INVESTIGATOR_4382] ™Motili ty Capsule), a wearable data recorder 
(SmartPi[INVESTIGATOR_4382] ™Motilit y Recorder), and a software program (MotiliGI™).  The system measures 
whole gut and regional (stomach, small bowel, and colon) transit time by [CONTACT_229491], 
pH,and temperature through out the GI tract ( Medtronic 2017 ).  The US Food and Drug 
Administrati on has approved the system for the evaluat ion of adult patients with suspected 
delayed gastri c empt ying and the evaluat ion of colonic transit time (CTT) and combined small 
and lar ge bowel  transi t time (SLBTT) in patients with chronic const ipation (Saad and Hasler 
2011; Medtronic 2017 ).  The American and European Neurogastroenterology  and Motilit y 
Societies recognized the WMC techno logy as a validated, standardized, object ive measure of GI 
transi t time and recommended its use for testing in individuals wit h suspected alterations of GI 
motility (Rao et al. 2011).   Patients’ baseline transit times will be measured with the WMC prior 
to firs t dose of the CGRP antagonist in pat ients with migraine deemed eligible by [CONTACT_229197]. Two weeks fo llowing study  treatm entadministration, a second WMC will be 
administered to obtain co mparative transi t time values to one’s baseline for those patients in each 
treatm ent group.
3.2. Background
Recent publicat ions have illustrated that CGRP can induce pharmaco logical effects at the CGRP 
receptor, as well as being a potent agonist at the amylin 1 (AMY1) receptor.  As such, an 
antibody  that binds to the CGRP receptor (erenumab) will block the effects of CGRP at the 
CGRP receptor, but will not inhibit the effects of CGRP at the AMY1 receptor.  In contrast, an 
antibody  that binds to CGRP itself (galcanezumab) will inhibit the pharmaco logical effects of 
CGRP at both the CGRP and AMY1 receptors ( Figure CGBC .3.1).  Amylin is an agonist at the 
AMY1 receptor, but is a very  weak activator of the CGRP receptor (Hay  2017; Hay  et al . 2018 ; 
I5Q-MC-CGBC(a) Clinical Protocol Page 16
galcanezumab (LY2951742)Hargreaves and Olesen 2019 ).  The effects of amylin at the AMY1 rece ptor will  persist in the 
presence of either ant ibody .
Calcitonin gene -related pepti dereceptors are l ocated throughout the GI system  of rodents and 
humans, including both the small and large intest ines.  Calcitonin gene -related pepti deinfusio n 
has been re ported to cause GI symptoms in 93% of human subjects (Falkenberg and Olesen
2019).   Addit ionally , CGRP (administered intraperitoneally) has been shown to cause diarrhea in 
rodents that can be blocked by a CGRP ant ibody (Kaiser et al. 2017).  Invest igators have 
reported constipation with treatm ent for migraine pre ventionin clinical trials of select ive CGRP 
receptor antagonists that are higher (Ho et al. 2014; ClinicalTrials.gov 2018; Ashina et al. 2019 ; 
Aimo vig package insert, 20 20
)than the CGRP antagonists at the ligand (Stauffer et al . 2018 b; 
Silberstein et al. 2019 ).
Alternat ively, act ivation of amylin receptors induce sstasis of the GI system . Amylin receptors 
are found on nerves project ing to the GI tract.  The amylin analog, pramlint ide, slows gastri c 
emptying and is contraindicated in pat ients with gastroparesis.  An amylin antagonist (AC187) 
accelerates gastric emptying in rats.
One possible explanation for the differences between reported frequencies of const ipation in
Phase [ADDRESS_276219] at the CGRP ligand versus the CGRP receptor could 
involve the effects of CGRP at the AMY1 receptor (Hay et al. 2018; Stauffer et al. 2018b; 
Aimo vigpackage insert, 2020; Ashina et al. 2019 ;Hargreaves and Olesen 2019; Robbins 2019 ; 
Silberstein et al. 2019 ).  By[CONTACT_229495] ,the CGRP receptor antagonist 
(erenum ab)woul d decrease the motilit y-enhancing characterist ics of CGRP whil e maintaining , 
or perhaps increasing, the GI m otility-slowing effects vi a AMY1 receptor activat ion.  
Alternat ively, the CGRP antagoni st acting at the ligand woul d inhibit the m otilit y-enhancing and 
motility-slowing effects of CGRP at the CGRP and AMY1 rece ptors, respectively, with the net 
effect being little to no change in GI transit time.   This hypothesis will be studied in this clinical 
trial.
I5Q-MC-CGBC(a) Clinical Protocol Page 17
galcanezumab (LY2951742)Abbreviations:  AMY1 = amylin 1; CGRP = calcitonin gene -related peptide .
Figure CGBC. 3.1. Mechanism of action of CGRP monoclonal antibodies .
3.3. Benefit/Risk Assessment
Galcanezumab is a humanized mo noclonal  antibody  that potently  and select ively binds to CGRP 
and prevents its bio logical act ivity without bl ocking the CGRP receptor.  The efficacy o f 
galcanezumab inthe prevent ion of migraine has been demonstrated in three Phase [ADDRESS_276220] ion compared withplacebo in patients with epi[INVESTIGATOR_39751] c and chroni c migraine (Detke et al. 
2018; Skljarevski et al. 2018; Stauffer et al. 2018 a).  Across Phase 2 and Phase 3 clinical studies 
in patients with migraine, galcanezumab exhibited a favorable safet y profile at doses up to 300 
mg every  4 weeks for 3 months, or 240 mg monthly for up to 1 y ear(Camporeal e et al . 2018; 
Dodi ck et al . 2014; Oakes et al . 2018; Skljarevski et al . 2018 ; Stauffer et al. 2018a )
.  The 
incidences of serious adverse events (SAEs) and discontinuations due to AEs were low, and 
treatm ent-emergent adverse events (TEAEs) were generally of mild to moderate severit y.  In the 
Phase [ADDRESS_276221] been reported with 
galcanezumab.
More informat ion about the known and expected benefits, risks, SAEs ,and reasonably 
anticipated AEs of galcanezumab are to be found in the Investigator’s Brochure (IB).

I5Q-MC-CGBC(a) Clinical Protocol Page 18
galcanezumab (LY2951742)Erenum ab is a huma n monoclonal ant ibody that antagonizes the CGRP receptor.  The efficacy of 
erenumab for the prevent ion of migraine has been demonstrated in three Phase 3 rando mized, 
doubl e-blind trials (Goadsby  [CONTACT_2297] . 2017; Tepper et al. 2017 ; Dodick et al. 2018 ).  Erenum ab [ADDRESS_276222] commo n adverse reactions (with an incidence of at least 2% for either 
dose of erenumab and at least 2% greater than placebo ) were inject ion site reactions ,
constipation ,and cram ps/muscle spasms (Ashina et al. 2019 ; Aimo vigpackage insert, 2020).
Hypersensi tivity react ions (including rash, angioedema, and anaphylaxis ), 
const ipation with 
serious com plicat ions,and n ew-onset or worsening of pre -exist ing hypertensio n have been 
reported with erenumab in postm arketing experience.
The ri sks of WMC include capsule retent ion and aspi[INVESTIGATOR_57774],which rarely and very rarely are 
reported .  With regard to the cases of capsule retention, they  resolved either without intervention 
or wi th endoscopy /colonoscopy . Surgery  was required for resolut ion in one instance of capsule 
small bowel retention that led to ident ificat ion of a stricture . 
To minimize these risks, p atients wi th a history  of GIsurgery , 
a self -reported hi story  of gastric 
bezoars, swallowing disorders, severe dysphagia to food or pi[INVESTIGATOR_3353], suspected or known strictures, 
fistul as, or phy siological/mechanical  GI obstructi onare excluded to participate in the study .
Patients shoul dnot undergo a magnet ic resonance imaging (MRI) test until capsule passage is 
confirmed by [INVESTIGATOR_345] o f the MotiliGI ™graph or x -ray of ki dneys, ureter ,and bladder. If a WMC
is in the body  during an MRI test, there is a risk of damage to the GI tract.
I5Q-MC-CGBC(a) Clinical Protocol Page 19
galcanezumab (LY2951742)4.Objectives and Endpoints
Table CGBC .4.1shows the object ives and endpo ints of the study .
Table CGBC .
4.1. Objectives and Endpoint s
Objectives Endpoints
Primary Objective
To evaluate colonic transit time (CTT) in patients 
with migraine 1week prior to and 2weeks after
administration of an initial loading dose of 
galcanezumab 240 mg or erenumab 140 mg.Change f rom baseline inCTT after administration of 
galcanezumab or erenumab within each treatment group in 
hours at the end of Week 2.
Secondary Objective s
To evaluate transit time of the following segments 
of the gastrointestinal ( GI)tract 1week prior to and 
2weeks after administration of galcanezumab or 
erenumab:
whole gut
gastric emptying
small bowel
combined small and large bowel.Change f rom baseline in GI transit time in each of the 
following segments after administration of galcanezumab 
or erenumab within each trea tment group at the end of 
Week 2 :
Whole gut transit time (WGTT) ,in hours
Gastric emptying time (GET) ,in hours
Small bowel transit time (SBTT)
,in hours
Combined small and large bowel transit time 
(SLBTT) ,in hours .
To evaluate the frequency of contractions, motility 
index ,and area under the pressure curve (AUC) by 
[CONTACT_229496].Changes in pressure parameters from baseline:
Contraction Freq/Min
Motility  Index =  ln (# of contractions x 
∑pressure amplitudes +1)  
Area under the Pressure Curve .
To evaluate number of weekly spontaneous bowel 
movements (un -aided by [CONTACT_223687], enemas, or 
suppositories) prior to and after administration of 
galcanezumab or erenumab.Change f rom baseline in number of weekly spontaneous 
bowel movements after administration of galcanezumab or 
erenumab within each treatment group at Weeks 2 and 4.
To evaluate GIsymptom rating scale (GSRS) prior 
to and after administration of galcanezumab or 
erenumab.Change f rom baseline in GSRS after administration of 
galcanezumab or erenumab within each treatment group at 
Weeks 2 and 4 .
To evaluate the Bristol stool form scale (BSFS)
prior to and after administration of galcanezumab or 
erenumab .Change f rom baseline in BSFS after administration of 
galcanezumab or erenumab within each treatment group at 
Weeks 2 and 4.
Tertiary /Exploratory Objective s
To evaluate the transit time between galcanezumab 
and erenumab fo r
whole gut
gastric emptying
small bowel
colon
combined small and large bowel.Change f rom baseline in transit time after administration 
of galcanezumab orerenumab between treatment group s at 
the end of Week 2 for
WGTT ,in hours
GET ,in hours
SBTT ,in hours 
CTT ,in hours
combined SLBTT ,in hours .
To evaluate number of weekly spontaneous bowel 
movements (un -aided by [CONTACT_223687], enemas, or 
suppositories) prior to and after administration of 
galcanezumab or erenumab. Change f rom baseline in num ber of weekly spontaneous 
bowel movements after administration of galcanezumab or 
erenumab between each treatment group at Weeks 2 and 4.
I5Q-MC-CGBC(a) Clinical Protocol Page 20
galcanezumab (LY2951742)Objectives Endpoints
To evaluate GSRS prior to and after administration 
of galcanezumab or erenumab.Mean change difference from baseline in GSRS scores 
after administration of galcanezumab or erenumab 
between treatment groups at Weeks [ADDRESS_276223] -
treatment.
I5Q-MC-CGBC(a) Clinical Protocol Page 21
galcanezumab (LY2951742)5.Study  Design
5.1. Overall Design
Study  CGBC is a mult icenter, randomized, single -blind ,Phase 4study with 2study  periods in 
patients with migraine who are deemed eligible for preventive treatment by [CONTACT_31821] .  The study  has 2 peri ods:a screening period to determine patient eligibilit y and 
lead-in wit h a baseline WMC test ;and an single -blind treatm ent period with a post-study 
treatm ent WMC test.
Study  governance considerations are described in detail in Appendix 2 .
Figure CGBC .5
.1illustrates the study design.
Abbreviations:  LD = loading dose; Single -Blind = only the investigator, site personnel ,
and spo nsor will know the randomized treatment after randomization; SP = stud y 
period; WMC = wireless motility capsule .
Figure CGBC .5.1 . Illustration of study design for Clinical Protocol I5Q-MC-CGBC .
Study Period I :  The study and potential risks will be explained to the patient at Visit 1.  The 
inform ed consent form (ICF) must be signed before any  study  procedures are performed.
The screening and baseline GI transi t time visit (Visi t 1) will  consist of a full clinical assessment, 
including a comprehensive medical evaluat ion docum enting medical history , and a physical 
exam ination(see Schedule of Act ivities, Secti on 2)to confirm eligibilit y.  Visi t 2 includes 
administration of the WMC and recei pt of  recorder to patients meet ing all eligibilit y 
requi rements .

I5Q-MC-CGBC(a) Clinical Protocol Page 22
galcanezumab (LY2951742)Study Period II :  At the start of the single- blind treatm ent period(Visit 3),patients will be 
rando mized in a 1:[ADDRESS_276224] scheduled procedure shown in the Schedule o f 
Activities(Secti on 2)for the last patient.
5.4. Scientific Rationale for Study Design
Refer to Section 3.1for further inform ation.
5.5. Justification for Dose
A galcanezumab 240 -mg loading dose ( 2consecutive inject ions of 120 mg each) or a dose of 
140 m g erenumab ( 2consecutive inject ions of 70mg each) will be administered by [CONTACT_229497] .
I5Q-MC-CGBC(a) Clinical Protocol Page 23
galcanezumab (LY2951742)6.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enrollment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at 
screening:
Patient and Disease Characteristics
[1] Patients are 18 to 55years of age (inclusive) at the time of screening .
[2] Have a diagnosis of migraine (1.1 and 1.2 ICHD) , with or without aura, as 
determined by [CONTACT_229498] –3rd 
edition gui delines (ICHD -3 2018).
[3] Have a frequency  of less than 15 m onthly headache day sof which up to 14 
can be migraine headache days .
[4] Patients can be on no m ore than 1 other migraine prevent ive treatm ent(except 
for tricyclic ant idepressants and verapamil) as long as:
that pati ent has had a stable dose of the oral migraine preventive treatm ent for a 
minimum o f 2 months
or
patients that have rece ivedonabotulinumtoxinA for a minimum of 2 cycles pri
or 
to Visit 1.
Informed Consent and Patient Agreements
[5] A re able and willing to give signed informed consent .
[
6]Are reliable and willing to fo llow study  procedures .
[
7] Male patients must agree to use a reliable method of birth control during the 
study as well as for 5 m onths after dosing with study  treatm ent.
[
8]Women of childbearing potential must test negative for pregnancy at the time 
of enro llment based on a urine pregnancy test.
[
9]Women of childbearing potential who are abstinent from sexual intercourse 
must agree to remain abst inent during the study as well as for 5 months after 
dosing wit h study  treatm ent.
I5Q-MC-CGBC(a) Clinical Protocol Page 24
galcanezumab (LY2951742)[10] Otherwi se, women of childbearing potential must agree to use 1highly 
effect ive method of contraception (including a mal e partner wh ohas had a 
vasectomy )
, or a combinat ion of 2effect ive methods of contraception during 
the study  as well  as for 5 m onths after dosing with study  treatm ent.Birth 
control  is not requi red if the female is infertile due to surgical sterilizat ion 
(hysterectomy, or at least 6 weeks after surgical bilateral oophorectomy or 
tubal  ligation) confirmed by [CONTACT_229499] m enopause.
[11] Agree not to post any  personal medical data related to the study  or 
inform ation related to the study  on any websi te 
or soci al media si te (e.g., 
Facebook, Twitter, LinkedIn, Google+, etc.) until the ent ire trial has 
completed.
6.2. Exclusion Criteria
Patients will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening:
Medical Conditions
[
12]Prior to Vi sit 1, less than 3 bowel mo vements in the previous 7 days .
[
13]Patients wi th a history of irritable bowel  syndrom e(IBS) or chronic 
constipation.
[
14]Patients wi th a self -reported hi story  of gastric bezoars, swallowing disorders, 
severe dysphagia to food or pi[INVESTIGATOR_3353], suspected or known strictures, fistulas ,or 
physio logical/mechanical GI obstruction .
[
15] H istory of GI surgery  with the except ion ofcholecystectomy , appendectomy ,
or Nissen fundoplication .
[16] History  of any abdominal surgery within the past 3 months.
[
17]History  of bariatri c surgery .
[18]History  of Crohn’s disease , celiac disease, ulcerat ive co litis,or divert iculitis.
[19]Patients wi th type 1 ortype 2 d iabetes .
[20] Patients wi th cardi ac pacemakers or other implanted or portable 
electrom echanical  device .
[
21]Patients wi th a body  mass index (BMI) of ≥40kg/m2.
[22] Women who are pregnant or nursing.
[23]History  of drug or al coho l abuse/dependence wit hin 1 y ear pri or to Vi sit 1 
(excessive or compulsive use as judged by  [CONTACT_17062]), or currently using 
drugs of abuse (including opio ids, barbiturates, and marijuana), or any 
prescribed or over- the-counter medicat ion in a manner that the invest igator 
considers indicat ive o f abuse/dependence.
I5Q-MC-CGBC(a) Clinical Protocol Page 25
galcanezumab (LY2951742)[24] Have an acute, serious, or unstable medical condit ion that, in the judgment of 
the invest igator, indicates a medical problem that would preclude study 
participat ion
.
[25] M yocardial  infarct ion, unstable angina, percutaneous coronary  intervent ion, 
coronary  artery  by[CONTACT_9292], st roke, deep vein thrombosis, or pulmo nary 
embo lism within [ADDRESS_276225] planned cardio vascular 
surgery  or percutaneous coronary  angi oplasty .
[26]Patients who, in the clinician’s judgment, are actively suicidal and therefore 
deem ed to be at significant ri sk for sui cide, or have had clinically significant 
suicidal ideation within the past m onth (e .
g., includes some plan or intent to 
act), or have had any  suicidal  behavi or wi thin the past m onth.
Prior/Concomitant Therapy
[
27]Patients currentl yreceiving a mAb CGRP antagonist or hav ereceived a mAb
CGRP antagonist within the past 6 months prior to Visit 1 .
[28] Have received an oral CGRP antagoni st(gepant )14days prior to Visit 1.
[29] Known hypersensit ivity to m onocl onal antibodi es or other therapeutic 
proteins, or to galcanezumab.
[
30]Known allergy  to Sm artBar ingredients including grano la (rolled oats, 
evaporated cane juice, expeller pressed cano la oil, defatted wheat germ, oat 
flour, brown ri ce syrup, m olasses, salt, natural flavor, soy  lecithin), whey 
crisp, ri ce syrup, corn sy rup, whey protein isolate, invert sugar, puffed wheat, 
apples, m altodextrin, sorbi tol, appl e juice concentrate, partially  hydrogenated 
vegetable o il (cottonse ed, soybean), honey , natural and artificial flavor, salt, 
gluten, vanilla .
[
31]Medicat ions known to alter GI transit times including opio ids, tricylic 
antidepressants, verapamil, and medicat ions that can affect the WMC test such 
as proton pump inhibitors, are excluded from the study [ADDRESS_276226] of 
excluded medicat ions.
Prior/Concurrent Clinical Trial Experience
[32] Are current ly enrolled in any other clinical study  involving an invest igational 
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study
.
Other Exclusions
[33] In the opi[INVESTIGATOR_1649] o f the invest igator, have other issues that would interfere wi th 
compliance wi th the study  requi rements and com pletion of  evaluat ions 
requi red for thi s study .
I5Q-MC-CGBC(a) Clinical Protocol Page 26
galcanezumab (LY2951742)[34] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted.
[
35] A re Lilly  empl oyees or are em ployees of Medtronic .
[
36] A re unwilling or unable to comply  with the use of a data collect ion device to 
directly record data from the subject .
6.3. Lifestyle Restrictions
No vigorous exercise , such as sit
-ups, abdominal crunches, orprolonged extrem e exercise s,
shoul d be perform ed throughout the duration of the WMC test,which is approximately 5 days .
Patients shoul d maintain consistent dietary  habits throughout the durati on of the study  (from 
Visit 1 to Vi sit 5).
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be
considered for rescreen once, with approval fro m Lilly Medical for only  the cri teria shown 
below.  The i nterval between screening and rescreening must be at least 45 days or longer if 
requi red for the specified time frames in the inclusio n/exclusio n criteria or concomitant 
medicat ion list.  If rescreening is performed, the individual must sign a new ICF and will be 
assigned a new ident ificat ion number.
Inclusio n criterion 1:  If patients are less than 18 years old at the time o f informed 
consent, they  may be rescreened when they reach 18 years of age during the study  
enrollment period.
Exclusio ncriterion 27, 28, and 31:  Patients using a concomitant medication that 
requi res a stable dose for a specific duration prior to Visit 1 may be rescreened if 
additional time is needed to meet the duration requirement.
I5Q-MC-CGBC(a) Clinical Protocol Page 27
galcanezumab (LY2951742)7.Treatment s
7.1. Treatments Administered
This study  involves a n evaluat ion of GI transit time in patient swho receive galcanezumab 
240mgadministered by [CONTACT_229500] [ADDRESS_276227] ion.Both galcanezumab and erenumab will be administered by [CONTACT_229501] (AI) pen at Visit 3of the study .  Table CGBC. 7.1shows the treatment 
regimens.
Table CGBC. 7
.1. Treatment Regimens
RegimenDose
Day 7 ± 2
Galcanezumab 240 mg 240 mg
(2 120-mg SCinjection)
Erenumab 1 40 mg 140 mg
(270-mg SCinjection)
Abbreviation:  SC = subcutaneous.
The invest igator or his/her designee is responsible for
verifying that instructions are fo llowed properly
maintaining accurate records of study  treatm entdispensing and collect ion, and
at the end of the study ,returning all unused medication to Lilly, or its designee, 
unless the sponsor and sites have agreed that all unused medicat ionsareto be 
destroy ed by  [CONTACT_4179], as all owed by l ocal law.
7.1.1. Packaging and Labe ling
Galcanezumab and erenumab will be supplied as an injectable sol ution in 1
-mL, single -dose, 
prefilled, disposable AI pen .Each AI pen of galcanezumab is designed to deliver 1 20 m g/mL , 
and each AI pen of erenumab is designed to deliver 70 mg/mL. All AI pens will be supplied in 
single pen cartons, with thesite to sel ect the appropri ate quanti ty of AI pens, specific to the 
planned treatm ent schedule. Two galcanezumab AI pens are needed for the galcanezumab (240 
mg)treatm ent.  Two erenumab AI pen sareneededfor the erenumab (140 m g) treatm ent.
The commercial products being provided will be labeled wit h a commercially approved product 
label.  Each commercial product package is to have a “For CT use only ”label .
7.1.2. Medical Devices
The commercial medical devices provided for use in the study  are AI pe nsand the Sm artPi[INVESTIGATOR_4382]™ 
system .  
The SmartPi[INVESTIGATOR_4382]™ mot ility testing system includes the SmartPi[INVESTIGATOR_4382]™ motilit y capsule
(WMC) , the MotiliGI™ software, and the SmartPi[INVESTIGATOR_4382]™ motilit y recorder .
I5Q-MC-CGBC(a) Clinical Protocol Page 28
galcanezumab (LY2951742)7.2. Method of Treatment Assignment
Patients who meet all criteria for enrollment will be randomized to single -blind treatm ent at 
Visit 3.  Assignment to treatment groups will be determined by a computer -generated random 
sequence using an interactive web- response system (IWRS).
To achieve between -group com parabilit y, the randomizat ion will be stratified by [CONTACT_3725], BMI 
category (<30kg/m 2, ≥30 kg/m 2),and by [CONTACT_229502] (<8 migraine headache 
days versus ≥8 migraine headache days) .
7.2.1. Selection and Timing of Doses
The study treatm entwill be administered only once at Visi t 3.
7.3. Blinding
This is a single
-blind study .Only the investigator, site personnel ,and spons or will know the 
rando mized treatment after rando mizat ion. Site Personnel are responsible to ensure pati ents 
remain blinded to treatment (i.e., patients must not see the AI pens before, during ,or after the 
drug administration). See the Manual of Operat ionsfor further details regarding blinding.
7.4. Dosage Modification
Not applicable .
7.5. Preparation/Hand ling/Storage/Accountability
The invest igator or his/her designee is responsible for the fo llowing:
confirming appropriate temperature condit ions have been maintained during 
transi t for all study  treatm ent received and any discrepancies are reported and 
resolved before use of the study  treatm ent.
ensuring that only participants enro lled in the study may receive study treatment 
and only  authori zed si te staff may  supply  or administer study  treatm ent. All study 
treatm ents m ust be stored in a secure, environmen tally controlled, and m onitored 
(manual  or autom ated) area i n accordance with the labeled storage condit ions 
with access limited to the invest igator and authorized site staff .
the invest igator, inst itution, or the head of the medical inst itution (where 
applicable) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as receipt, reconciliat ion,and final disposit ion records).
The study  treatm entmust be stored according to the storage requirements printed onto the 
commercial label.
To administer the gal canezumab or erenumab injections, the investigat ional sites are to refer to 
the commercial package insert for the preparation and handling instructions o f each study  
treatm ent.
I5Q-MC-CGBC(a) Clinical Protocol Page 29
galcanezumab (LY2951742)7.6. Treatment Compliance
Patient com pliance with study  medicat ion will be assessed at the dosing visit.  Deviation(s) fro m 
the prescribed dosage regimen should be recorded in the electroni c case report form ( eCRF ).
7.7. Concomitant Therapy
The list of excluded medicat ions and procedures is provided in the Manual o f Operati ons.  Any 
changes in the list of allowed/not allowed medicat ions will be co mmunicated to investigators and 
will not constitute a protocol amendment.
7.8. Treatment after the End of the Study
Study  treatm entwill not be made available to patie nts after conclusion o f the study .
I5Q-MC-CGBC(a) Clinical Protocol Page 30
galcanezumab (LY2951742)8.Discontinuation Criteria
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Possible r easons leading to permanent discontinuatio n of study  treatm ent:
Subject Decision
othe pati entrequests to discont inue study  treatm ent.
In addit ion, pati ents will  be discont inued fro m the study  treatm entin the fo llowing 
circumstances:
oWMC retenti on or aspi [INVESTIGATOR_229479] m the study  prem aturely for any  reason shoul d com plete AEand other 
follow-up procedures per Section 2(Schedule of Activit ies), Section 9.2(Adverse Events) ,and 
Secti on 9.4(Safet y) of this protocol .
8.1.2. Temporary Discontinuation from Study Treatment
Not applicable .
8.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ifies a pati ent who di d not m eet enrollment cri teria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm ent unless there 
are extenuat ing circumstances that make it medically necessary for the patient to conti nue study  
treatm ent.  If the invest igator and the sponsor clinical research physician (CRP )/clinical research 
scientist ( CRS )agree it is medically appropriate to continue, the invest igator must obtain 
docum ented approval  from the sponsor CRP /CRS to allow the inadvertently enrolled patient to 
continue in the study  with or wi thout study  treatm ent.Safet y follow-up is as outlined in Sect ion 
2(Schedule o f Activities), Section 9.2(Adverse Events), and Section 9.4(Safet y) of the 
protocol .
8.2. Discontinuation from the Study
Patients will be discont inued in the fo llowing ci rcumstances:
enrollment in any other clinical study  involving an study  treatm entor 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and Good 
Clinical Practice (GCP)
investi gator decisio n
I5Q-MC-CGBC(a) Clinical Protocol Page 31
galcanezumab (LY2951742)othe invest igator decides that the patient should be discontinued from the 
study
oif the pat ient, for any  reason, requi res treatm ent with another therapeutic 
agent that has been demonstrated to be effect ive for treatm ent of the study  
indicat ion, discont inuat ion from the study  occurs pri or to introducti on of  
the new agent
patientdecision
othe patientrequests to be withdrawn fro m the study
patient becom es pregnant .
Patients di scont inuing fro m the study  prem aturely for any  reason shoul d com plete AEand other 
safet y follow
-up per Secti on2(Schedule of Activit ies), Section 9.2(Adverse Events) ,and 
Secti on9.4(Safet y) of this protocol .
8.3. Lost to Follow -Up
A patientwill be considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_941] s tudy site.  Site personnel are expected to make 
diligent attempts to contact [CONTACT_57986] a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_4179].
Site personnel, or an independent third party , will  attem pt to collect th e vital status of the patient 
within legal  and ethical  boundaries for all patients randomized, including those who did not 
receive study  treatm ent.  Public sources may  be searched for vital status informat ion.  If vital 
status is determined, this will be d ocum ented and the pat ient will not be considered lost to 
follow-up.
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
I5Q-MC-CGBC(a) Clinical Protocol Page 32
galcanezumab (LY2951742)9.Study  Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
9.1. Efficacy Assessments
9.1.1. Primary Assessment of GI Transit Time
The WMC (Medtronic 2017) measures who le gut and regional gut (stomach, small bowel, and 
colon) transi t times through measurement of pH, pressure, and temperature throughout the GI 
tract.   Once enro lled into study, the pati ent will be asked to eat a SmartBar, followed by 
[CONTACT_229503] [ADDRESS_276228] ible single -use, 2 712mm cylindrical capsu le.  Data are
transferred to the accompanied wearable external data 
recorder and displayed and analyzed using 
MotiliGI ™versi on 3.1software ( Medtronic 2017 ).
The baseline and postbaseline WMC test will be assessed by [CONTACT_229504].
9.1.2. Secondary Assessment Scales
Gastrointestinal Symptom Rating Scale .  The Gastrointestinal Symptom Rating Scale (GSRS) 
is avalidated 15-item quest ionnaire that evaluates the 5commo n symptom s of G Idisorders: 
abdo minal pain, reflux, indigest ion, const ipation
,and diarrhea. Items ask about the past week 
using a 7 -point categori cal response scale from  no discomfort to very  severe di scomfort (Revicki 
et.al 1998 ; Khanna 2017 ).
Bristol Stool Form Scale. The Bristol Stool Form Scale (BSFS )is a 7-point ordinal scale of 
stool  types ranging fro mthe hardest (Ty pe 1) to the softest (Ty pe 7) . Sympt oms of const ipation 
arerelated to harder stools (Ty pe
s1 and 2) and symptoms of diarrhea are rel ated to loose/liqui d 
stools (Ty pes6 and 7) . Overall, s tool Type 3 to 5 are considered normal.  BSFS provides the 
patient wi th a pi[INVESTIGATOR_229480]  (Blake et al. 2016).
9.1.3. Appropriateness of Assessments
Theefficacy and safet y assessments used in this study  have been well doc umented and are 
generally regarded as reliable, accurate, and are relevant for use in thi s study .
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each laborator y safety  report.
I5Q-MC-CGBC(a) Clinical Protocol Page 33
galcanezumab (LY2951742)The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the study  treatm ent
or the study , or that caused the patientto discont inue the study  treatm entbefore completing the 
study .  The patientshoul d be f ollowed up until the event resolves, stabilizes with appropriate 
diagnosti c evaluat ion, or is reasonably  explained.  The frequency of follow -up evaluat ions of the 
AE is left to the di screti on of  the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
The invest igator will record all relevant AE and SAE informat ion in the eCRF.  After the ICF i s 
signed, study  site personnel  will record via eCRF the occurrence and nature of each pat ient’s 
preexist ing condit ions, including clinically significant signs and symptoms of the disease under 
treatm ent in the study .  In addit ion, site person nel will record any  change in the condi tion(s) and 
any new condit ions as AEs . Invest igators should record their assessment of the potential 
relatedness of each AE to protocol procedure and study  treatm ent, via eCRF .
The invest igator will interpret and doc ument whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment, or pathologies.
A “reasonable possibilit y” means that there is a cause -and-effect rel ationship between the study  
treatm ent, study  device ,and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s study  treatm entis discontinued as a result of an AE, study  site personnel  must 
report thi s to Lilly or i ts desi gnee via eCRF , clarifying if possible the circumstances leading to 
any dos agemodifications, or discontinuations of treatment.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1 of the f ollowing outc omes:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience ( i.e., immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
I5Q-MC-CGBC(a) Clinical Protocol Page 34
galcanezumab (LY2951742)important medical events that may not be immediately life-threatening or result in 
death or hospi[INVESTIGATOR_82340] m ay jeopardi ze the patient or m ay require intervent ion 
to prevent one of the other outcomes listed in the definit ion.  Examples of such 
medical events include allergic bronchospasm requiring intens ive treatm ent in an 
emergency room  or at hom e, blood dy scrasias or convulsio ns that do not result in 
inpat ient hospi [INVESTIGATOR_3094], or the development of drug dependency or drug abuse.
when a condit ion related to the AI pen necessitates medical or surgical 
intervent ion to preclude either perm anent impai rment of  a body  functi on or 
perm anent dam age to a body  structure, the seri ous outcom e of “requi red 
intervent ion” will be assigned.
All AEs occurring after signing the ICF are recorded in the e CRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the patient has signed the ICF and has 
received study  treatm ent.  However, if an SAE occurs after signing the ICF, but prior to 
receiving study  treatm ent, the SAE should be reported to the sponsor as per SAE reporting 
requi rements and timelines (see Sect ion 9.2) if it is considered reasonably possibly related to 
study procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within [ADDRESS_276229] igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed by [CONTACT_229505] -specific SAE forms.  This 24 -
hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow-up SAE 
inform ation.
Pregnancy ( during maternal or paternal exposure to study  treatm ent) does not m eet the definit ion 
of an AE.  However, to fulfill regulatory requirements any pregnancy should be reported 
following the SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discont inued and/or completed the study  (the patientdisposit ion eCRF has been co mpleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he or she considers the event reasonably possibly related to 
the study  treatm ent or study  parti cipati on, the investi gator m ust prom ptly notify Lilly.
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not l isted 
in the galcanezumab IB or the erenumab US package insert (USPI) and that the investigator 
ident ifies as related to study treatm entor procedure.  [LOCATION_002] [ADDRESS_276230] ive 2001/20/EC and the associated de tailed guidances or nati onal 
regul atory  requi rements in partici pating countri es requi re the reporting of S[LOCATION_003]Rs.  Lilly has 
procedures that will be fo llowed for the ident ification ,recording ,and expedited reporting of 
S[LOCATION_003]Rs that are consistent with globa l regulat ions and the associated detailed guidances.
I5Q-MC-CGBC(a) Clinical Protocol Page 35
galcanezumab (LY2951742)9.2.2. Complaint Handling
Lilly co llects product complaints on study  treatm entand drug delivery systems used in clinical 
studi es to ensure the safet y of study  parti cipants, moni tor qualit y, and to facili tate p rocess and 
product improvements.
Patients will  be instructed to contact [CONTACT_81129] a 
complaint or probl em wi th the study  treatm ent(galcanezumab or erenumab) or device (AI or 
WMC) so that the situation can be assessed.
9.3. Treatment of Overdose
Refer to the IBfor galcanezumab andtheProduct Label forerenumab .
9.4. Safety
9.4.1. Vital Signs
For each patient, vital signs measurements should be conducted according to the Schedule of 
Activities (Secti on 2).
Any clinically  significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study  treatm ent shoul d be reported to Lilly or 
its designee as an AE via eCRF.
9.4.2. Laboratory Tests
For each patient , the local urine pregnancy  test shoul d be conducted according to the Schedule of 
Activities (Secti on 2).
9.4.3. Immunogenicity Assessments
Not applicable.
9.4.4. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393].
[IP_ADDRESS]. Hepatic Safety Monitoring
Not applicable.
9.5. Pharmacokinetics
Not applicable.
9.6. Pharmacodynamics
Not applicable.
9.7. Genetics
Not applicable.
I5Q-MC-CGBC(a) Clinical Protocol Page 36
galcanezumab (LY2951742)9.8. Biomarkers
Not applicable.
9.9. Health Economics
Health Economics and Medical Resource Utilizat ion paramete rs arenot evaluated in this study.
I5Q-MC-CGBC(a) Clinical Protocol Page 37
galcanezumab (LY2951742)10.Statistical Considerations
10.1. Sample Size Determination
Assuming within -group m ean difference in CTT is about 4.[ADDRESS_276231] deviat ion of 
approximately  8, a sam ple of  30 pati ents in each treatment group will provide 80% power to 
detect the difference within the treatment group.  The total sample size for the study  woul d be 
60.
Assuming 20% screen failure rate, a pproximately 75patients may  be screened to enr oll60
patients intothe study .Eligible patients will be rando mized in a 1:[ADDRESS_276232] about 30 patients in each treatment group .
10.2. Populations for Analyses
For purposes of analysis, the intent-to-treat (ITT) populat ionwill be used. The ITTpopulat ion 
includes all pat ients who are randomized and received study  treatm ent.Other populat ion
smay 
be explored if appropriate, such as theITT populatio n excluding patients taking prohibited 
medicat ions that are known to have an effect on GI motilit yor the WMC test. 
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee. Details o f 
statist ical analysis methods will be described in the sta tistical analysis plan (SAP).
Unless otherwise specified, analyses will be conducted on the ITT populat ion,which will include 
all patients who are randomized and receive at least [ADDRESS_276233] ification for making the change, will be described 
in the SAP or the clinical study  report (CSR) .  Addit ional exploratory  analyses of the data will be 
conducted as deemed appropriate.
I5Q-MC-CGBC(a) Clinical Protocol Page 38
galcanezumab (LY2951742)10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
The number and percentage of ITT patients who complete the study  or di scontinue early  will be 
summarized for both treatm ent groups. A detailed descript ion of pat ient disposit ion will be 
provi ded at the end of the study .
Patient allocation by  [CONTACT_229506] . Patient allocation 
by [CONTACT_229507].
[IP_ADDRESS]. Patient Characteristics
The fo llowing pati ent characteri stics at baseline will be summarized by  [CONTACT_229508]:
demographic s(age, gender, ethnic origin, height ,weight, body  mass index)
medical history  and pre -exist ing condit ion
total gut and segmental transit times , and
GI symptom rating scale, SBM frequency, and Bristol  stool  form scale .
[IP_ADDRESS]. Concomitant Therapy
The proporti on of  patients who received conco mitant medicat ion will be summarized for all ITT 
pati
ents.
[IP_ADDRESS]. Treatment Compliance
Not applicable.
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary  object ive is to assess changes in CTT between pre-and post -drug administration 
within each treatm ent group.   The primary measure is the mean change fro m baseline in the CTT
2 weeks after drug administration within each treatment group.
The primary  analysis will be performed using an analysis of covariance (ANCOVA) model.  The 
analysis will include the categori cal effects of treatment and all rando mization stratificat ion 
factors (site, baseline migraine frequency, and BMI category ;see Sect ion 7.2),as well as the 
continuous baseline CTT . Least squares mean change fro m baseline in each treatment group will 
be tested to detect any  change in CTT between pre-and post -drug administration.
[IP_ADDRESS]. Secondary Analyses
For continuous secondary  measures wi th single postbaseline measurement, analysis will be 
perform ed using an ANCOVA model. The analysis will include the categori cal effects of 
treatm ent and all rando mizat ion stratification factors, as w ell as the continuous baseline value .
Least squares mean change fro m baseline in each treatment group will be tested to detect any  
changes between pre-and post -drug administration. Least squares mean change fro m baseline in 
[ADDRESS_276234] any  between -group differences.
I5Q-MC-CGBC(a) Clinical Protocol Page 39
galcanezumab (LY2951742)[IP_ADDRESS]. Tertiary/Exploratory Analyses
For continuous measures with repeated postbaseline measurements, change fro m baseline will be 
analyzed using a restricted maximum likelihood- based mixed effects model for repeate d 
measures technique (MMRM) .  The analysis will include the fixed categorical effects of 
treatm ent, all rando mizat ion stratificat ion factors, investigative site, week, and 
treatm ent-by-week interacti on, as well as the continuous fixed covariates of baseline value and 
baseline -by-week interacti on.Details of MMRM model are described in the SAP, and further 
details regarding tertiary  analyses are summarized in the SAP .
10.3.4. Safety Analyses
The safet y analys es will  be conducted for the single- blind treatm ent phase.
Safety data will be summarized by  [CONTACT_3227].
The safet y and tol erabilit y of treatm ent will be assessed by  [CONTACT_207522] :
TEAEs
oby [CONTACT_9560](PT)
oby [CONTACT_79075] ( SOC )
oby [CONTACT_41424] y
oconsidered to be related to study treatm entby [CONTACT_1697]
SAE s, and
AEsleading to discont inuat ion.
Treatment -emergent adverse events are defined as the reported AEs that first occurred or 
worsened during the postbaseline phase co mpared with baseline phase.  For each TEAE, the 
severit y level o f the event (mild, moderate, or severe) will be determined by [CONTACT_229509][INVESTIGATOR_3078] n.  The Medi cal Dict ionary for Regul atory  Activities(MedDRA ) Lowest Level Term will 
be used in the treatment -emergent computation.  For each Lowest Level Term , the m aximum  
severit y at baseline will be used as the baseline severit y.  If the maximum severit y during 
postbaseline is greater than the maximum baseline severit y, the event is considered to be 
treatm entemergent for the specific postbaseline period.  For each patient and TEAE, the 
maximum severit y for the MedDRA l evel being displayed ( PT, High Level Term, or SOC) is the 
maximum postbaseline severit y observed fro m all associ ated L owest Level Terms mappi[INVESTIGATOR_229481].
For events that are gender specific, the deno minator and computation of the percentage will 
include only  patients from the given gender.
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
Not applicable.
I5Q-MC-CGBC(a) Clinical Protocol Page 40
galcanezumab (LY2951742)10.3.6. Evaluation of Immunogenicity
Not applicable.
10.3.7. Other Analyses
Not applicable.
[IP_ADDRESS]. Health Economi cs
Not applicable.
[IP_ADDRESS]. Subgroup Analyses
Not a pplicable.
10.3.8. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the appropri ate Lilly medical director, or designee, will be consulted to determine
whether it is necessary to amend the protocol.
I5Q-MC-CGBC(a) Clinical Protocol Page 41
galcanezumab (LY2951742)11. References
Aamodt AH, Stovner LJ, Hagen K, Zwart JA. Comorbidity of headache and gastrointestinal 
complaints. The Head- HUNT Study . Cephalalgia. 2008;28(2):144 -51.
Aimo vig [[LOCATION_002] Package Insert ]. Thousand Oaks , CA: [COMPANY_010] Inc.; [ADDRESS_276235] for prevention of 
migraine: A pooled analysis of four placebo -controlled trials wit h long-term extensi ons 
[published online ahead of print 10 November 2019]. Cephalalgia . 
doi:10.1177/0333102419888222
.
Blake MR, Raker JM, Whelan K. Validit y and reliabilit y of the Bri stol Stool  Form  Scale in 
healt hy adults and patients with diarrhoea ‐predominant irritable bowel syndro me. Aliment 
Pharmacol Ther . 2016;44(7):693 -703.
Camporeale A, Kudrow D, Sides R, Wang S, Van Dy cke A, Sel zler KJ, Stauffer VL. A phase 3, 
long-term, open -label safet y study  of Galcanezumab in pat ients with migraine. BMC Neurol
2018;18(1):188.
ClinicalTrials.gov. Efficacy, safet y, and tol erabilit y of multiple dosing regimens of oral 
atogepant (AGN -241689) in epi[INVESTIGATOR_229482]. Available at: 
https://www.clinicaltrials.gov/ct2/show/results/[STUDY_ID_REMOVED]?cond=atogepant&rank=5&vie
w=results . Accessed October 1, 2019.
Detke HC, Goadsby [CONTACT_33263], Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcane zumab in chronic 
migraine: the randomized, double -blind, pl acebo -controlled REGAIN study . Neurology . 
2018;91(24):e2211- e2221.
Dodi ck DW, Ashina M, Brandes JL, Kudrow D, Lanteri -Minet M, Osipova V, Palmer K, Pi[CONTACT_1137] 
H, Miko lDD, Lenz RA. ARISE: a phase 3 rando mized trial of erenumab for epi[INVESTIGATOR_41989]. Cephalalgia. 2018;38(6):1026-1037.
Dodi ck DW, Goadsby  [CONTACT_33263], Spi [INVESTIGATOR_229483], Scherer JC, Sweeney  SP, Gray zel DS. Safet y and 
efficacy  of LY2951742, a m onocl onal antibody  to cal citonin gene -related pepti de, for the 
prevent ion of migraine: a phase 2, randomised, double -blind, placebo -controlled study . Lancet 
Neurol . 2014;13(9):[ADDRESS_276236] ivity. 
Cephalalgia
. 2019;39(suppl 1):191. Abstract IHC -PO-129.
FDA. FDA Adverse Events Reporting System (FAERS) Public Dashboard. Available at 
https://fis.fda.gov/sense/app/d10be6bb -494e- 4cd2 -82e4 -0135608ddc13/sheet/7a47a261-d58b-
4203- a8aa-6d3021737452/state/analysis . Accesse d October 31, 2019.
Goadsby  [CONTACT_33263], Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Pi[CONTACT_1137] H, 
Mikol DD, Lenz RA. A controlled trial of erenumab for epi[INVESTIGATOR_17730]. N Engl J Med . 
2017;377(22):2123 -2132.
I5Q-MC-CGBC(a) Clinical Protocol Page 42
galcanezumab (LY2951742)[ICHD -3] Headache Classificat ion Co mmittee of  the Internat ional Headache Societ y (IHS). The 
International Classificat ion of Headache Disorders, 3rd edit ion. Cephalalgia. 
2018;38(1):1 -211.
Hargreaves R, Olesen J. Calcitonin gene ‐related pepti de m odulators –the history  and renaissance 
of a new mi graine drug cl ass. Headache . 2019;59(6):951 -970.
Hay DL. Amylin. Headache . 2017;57
(suppl  2):89-96.
Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmaco logy of calci tonin/CGRP 
family o f pepti des: IUPHAR Review 25. Br J Pharmacol . 2018;175(1):[ADDRESS_276237] 
telcagepant for migraine prevent ion. Neurol . 2014;83(11):958 -966.
Kaiser EA, Rea BJ, Kuburas A, Kovacevich BR, Garcia
-Mart inez LF, Recober A, Russo AF. 
Anti-CGRP ant ibodies block CGRP -induced diarrhea in mice. Neuropeptides . 2017;64:95-99.
Khanna D, Hays RD, Shreiner AB, Melmed GY, Chang L, Khanna PP, Bolus R, Whit man C, 
PazSH, Hay s T, Rei se SP. Responsiveness to change and minimally  important differences of 
the pati ent-reported outcomes measurement informat ion system gastrointestinal symptoms 
scales. Dig Dis Sci . 2017;62(5):1186-1192.
Medtroni c. SmartPi[INVESTIGATOR_4382] ™GI Moni toring Sy stem: User Manual SmartPi[INVESTIGATOR_4382] ™ Sof tware v3.1. 
Minneapo lis, MN; 2017.
Oakes TM, Skljarevski V, Zhang Q, Kielbasa W, Hodsdon ME, Detke HC, Camporeale A, Saper 
JR. Safet y of galcanezumab in pat ients with epi[INVESTIGATOR_17730]: a rando mized 
placebo -controlled dose -ranging phase 2b study . Cephalalgia. 2018;38(6):1015-1025.
Rao SS, Camilleri M, Hasler WL, Maurer AH, Parkman HP, Saad R, Scott MS, Simren M, 
Soffer E, Szarka L. Evaluat ion of gastrointest inal transit in clinical practice: posit ion paper of 
the American and European Neurogastroenterology  and Motilit y Societies. 
Neurogastroenterol Motil. 2011;23(1):8 -23.
Revicki DA, Wood M, Wiklund I, Crawley J. Reliabilit y and validi ty of the Gastrointestinal 
Symptom  Rating Scale in pat ients with gastroesophageal reflux disea se. Qual Life Res . 
1998;7(1):75 - 83.
Robbins L. Erenumab side effects . Headache . 2019;59(7):1088 -1089.
Saad RJ, Hasler WL. A technical review and clinical assessment of the wireless motilit y capsule. 
Gastroenterol Hepatol . 2011;7(12):795.
Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, 
Cohen JM, Janka L, Yang R. Safet y and tolerabilit y of 
fremanezumab for the prevention of 
migraine : a pool ed analysis of phases 2b and 3 clinical trials. Headache . 2019;59 (6):880- 890 .
Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy  and safet y of 
galcanezumab for the prevent ion of epi[INVESTIGATOR_17730]: results of the EVOLVE -2 phase 3 
rando mized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454.
I5Q-MC-CGBC(a) Clinical Protocol Page 43
galcanezumab (LY2951742)Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluat ion of 
galcanezumab for the prevent ion of epi[INVESTIGATOR_17730]: the EVOLVE -1 randomized clinical 
trial. JAMA Neurol . 2018 a;75(9):1080-1088.
Stauffer VL, Wang S, Bangs ME, Oakes T, Carter J, Aurora SK. Safet y data fro m phase 3 
clinical studies co mpar ing galcanezumab and placebo in patients with epi[INVESTIGATOR_41955]. J Headache Pain . 2018 b;19(suppl 1):77.
Tepper S, Ashina M, Reuter U, B randes JL, Doležil D, Silberstein S, Winner P, Leonardi D, 
Mikol D, Lenz R. Safet y and efficacy o f erenumab for prevent ive treatment of chronic 
migraine: a randomised, double -blind, placebo -controlled phase 2 trial. Lancet Neurol . 
2017;16(6):425 -434.
I5Q-MC-CGBC(a) Clinical Protocol Page 44
galcanezumab (LY2951742)12. Appendices
I5Q-MC-CGBC(a) Clinical Protocol Page 45
galcanezumab (LY2951742)Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this trea tment.  An adverse event can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal ( study ) drug, whether or not related 
to the medicinal (study ) drug.
AI autoinjector
AMY1 amylin 1
ANCOVA analy sis of covariance
blinding/masking A single -blind study is one in which the investigator and/or staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and /orstaff and the patient are not.
BSFS Bristol Stool Form Scale
CGRP calcitonin gene -related peptide
CIOMS Council forInternational Organizations ofMedical Sciences
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compl iance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRP clinical research physician: Individual responsible for the medical conduct of the 
study.  Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician ,or other medical officer.
CRS clinical research scientist
CSR clinical study report
CTT colonic transit time
eCOA electronic clinical outcome assessment is a method of capturing data electronically in 
clinical trials.
eCRF electronic case report form
I5Q-MC-CGBC(a) Clinical Protocol Page 46
galcanezumab (LY2951742)Term Definition
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the study are 
those who have been assigned to a treatment.
enter Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives.
ERB ethical review board
GCP Good Clinical Practice
GET gastric emptying time
GI gastrointestinal
GSRS Gastrointestinal Symptom Rating Scale
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’s decision to participate .  Informed consent is documented by 
[CONTACT_3553] a written, signed ,and dated informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment 
groups, that is conducted before the final reporting database is created/locked.
ITT intent to tr eat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a patient ( i.e., the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to 
the planned course of treatment.
IWRS interactive web -response sy stem
mAb monoclonal antibod ies
MedD RA Medical Dictionary for Regulatory Activities
MMRM mixed effects model for repeated measures
MRI magnetic resonance imaging
PT Preferred Term
SAE serious adverse event
SAP statistical analysis plan
I5Q-MC-CGBC(a) Clinical Protocol Page 47
galcanezumab (LY2951742)Term Definition
Screen The act of determining if an individual meets minimum requirements to become part 
of a pool of potential candidates for participation in a clinical study.
SBTT small bowel transit time
SBM spontaneous bowel movement
SLBTT combined small and large bowel transit time
SOC System Organ Class
study treatment Any treatment (s),in this case marketed product(s), intended to be administered to a 
study participant according to the study protocol
S[LOCATION_003]R suspected unexpected serious adverse reaction
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens 
relative to the pretreatment state, and does not necessarily have to have a causal 
relatio nship with this treatment.
WGTT whole gut transit time
WMC wireless motility  capsule or the S martPi[INVESTIGATOR_229484]
I5Q-MC-CGBC(a) Clinical Protocol Page 48
galcanezumab (LY2951742)Appendix 2. Study  Governance Considerations
I5Q-MC-CGBC(a) Clinical Protocol Page 49
galcanezumab (LY2951742)Appendix 2.1.Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Appendix 2.1.1.Informed Consent
The invest igator is responsible for:
ensuring that the patient understands the nature of the study , the potential 
risks and benefits of participat ing in the study , and that thei r parti cipat ion is 
voluntary.
ensuring that informed consent is given by [CONTACT_229204].  This includes obtaining the appropriate signatures and dates 
on the informed consent form ( ICF) prior to the performance o f any protocol 
procedures and prior to the administration of study treatm ent.
answering any quest ions the pati ent m ay have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his or her participation in the study .
ensuring that a copy  of the ICF is provi ded to the participant or the 
participant’s l egal represen tative and is kept on file.
ensuring that the medical record includes a statement that written informed 
consent was obtained before the participant was enrolled in the study  and the 
date the written consent was obtained. The authorized person obtaining th e 
inform ed consent m ust al so sign the ICF.
Appendix 2.1.2.Recruitment
Lilly is responsible for the central recruit ment strategy  for pati ents.  Individual invest igators may 
have addit ional local requi rements or processes.
Appendix 2.1.3. Ethical Review
The invest igator must give assurance that the ethical review board (ERB) was properly 
constituted and convened as required by [CONTACT_157732] (ICH) 
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th
theprotocol and related amendments and addenda ,current Invest igator ’s
Brochure for galc anezumab, US Product Information for erenumab, and 
updates during the course of the study
ICF, and
I5Q-MC-CGBC(a) Clinical Protocol Page 50
galcanezumab (LY2951742)other relevant docum ents ( e.g., curricula vitae , adverti sements) .
Appendix 2.1.4. Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with the
consensus et hics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences (CIOMS ) Internati onal Ethi cal Gui delines
applicable ICH GCP Guidelines , and
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party .
Appendix 2.1.5. Investigator Information
Invest igators in this clinical trial should be neuro logists, headache specialists, or other specialists 
with experi ence in he adache clinical trials and treating patients with migraine .
Appendix 2.1.6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the planned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 2.1.7. Final Report Signature
[CONTACT_221083], indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study .
An invest igator selected by [CONTACT_229510] .  If 
this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_229511].
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for thi s 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendi x 2.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion of the case report 
forms (CRFs ), and study  procedures.
I5Q-MC-CGBC(a) Clinical Protocol Page 51
galcanezumab (LY2951742)make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_129237], tel ephone, and/or fax
review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion, and
conduct a qualit y review of the database .
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_81144], and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 2.2.1. Data Capture System
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  [CONTACT_92363] -provided electronic data capture system.
Invest igator sites will have cont inuous access to the electroni c clinical outcome assessment
(eCOA ) source docum ents during the study  and will  receive an archival copy  at the end of the 
study  for retenti on.
Any data for which the eCOA instrument srecord will serve to collect source data will be 
ident ified and documented by [CONTACT_140842]’s study file.
Case report form data will be encoded and stored in a clinical trial database.  eCOA data read by 
a central  reader , 
such as the WMC test, will be stored electronically . Subsequent ly,these data 
will be transferred from the central reader to the Lilly data warehouse .
Any data for which paper documentation provided by [CONTACT_229512] i dentified and documented by  [CONTACT_92366]’s study  file.  Paper 
docum entati on provi ded by  [CONTACT_229513], for example, a paper diary to collect 
patient-reported outcome measures ( e.g., a rating scale).
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
I5Q-MC-CGBC(a) Clinical Protocol Page 52
galcanezumab (LY2951742)Appendix 2.3. Study and Site Closure
Appendix 2.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP .
Appendix 2.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 2.4. Publication Policy
The publicat ion policy for Study  I5Q-MC-CGBC is described in theClinical Trial Agreement .
I5Q-MC-CGBC(a) Clinical Protocol Page 53
galcanezumab (LY2951742)Appendix 3. Protocol A mendment
I5Q-MC-CGBC(a) Summary
A Phase [ADDRESS_276238]
Overview
Protocol  I5Q-MC-CGBC(a) A Phase [ADDRESS_276239] has been 
amended.  The new protocol is indicated by [CONTACT_61504] (a) and will be used to conduct the study  
in place of any  preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are described in the 
following table:
I5Q-MC-CGBC(a) Clinical Protocol Page 54
galcanezumab (LY2951742)Amendment Summary for Prot ocol I5Q-MC-CGBC Amendment ( a)
Section # and Name [CONTACT_229517] -
label study to a single -blind study.This change was made to reduce potential for patient bias ,asthe frequency and 
consequences of constipation for erenumab and galcanezumab are not the same 
based on a recent USPI [INVESTIGATOR_229485].
Minor editorial changes Minor editorial changes were made toimprove clarity .
Title CGRP Antagonist has been clarified to mAb 
CGRP Antagonist.This clarification was made due to the recent approval of oral CGRP antagonists.
Section [ADDRESS_276240] been added to 
Visits 3, 4, and 5.The additional vital sign assessments were added due to the April 2020 update to 
the erenumab USPI [INVESTIGATOR_229486] -onset or 
worsening of pre -existing hypertension based on postmarketing information.
Section 6.1 Inclusion 
CriteriaChro nic migraine has been removed from 
Inclusion Criteri on[2].The chro nic migraine diagnosis was removed because this patient population hasa 
higher frequency of headaches per month ,which can be associated with more 
comorbidity.  Therefore, this c hange wa s made to reduce variation in the 
populatio n due to the small sample size and the exploratory nature of the study .  
Chro nic migraine was also removed from Inclusion Criterion [4] due to this 
change.
Inclusion Criteri on[3]has been added. The Inclusio n Criteri on[3](that patients must have a frequency of less than 15 
monthly migraine headache days of which up to 14 can be migraine headache days ) 
was added in response to the removal of ch ronic migraine from Inclusion Criteri on
[2].
Section 6.2 Exclusion 
CriteriaExclusion Criteri on[21]has been changed 
from “ Patients with a body mass index of 
≥50kg/m2” to“Patients with a body mass 
index (BMI) of ≥40kg/m2.”The BMI criteria was amended to be consistent with the BMI thresholds in the 
previousl y conducted Phase 3 trials. This change will l imitthe potential for 
outliers.
Exclusion Criteri on[28]has been added. Having received o ral CGRP antagonists has been added as an exclusion criteri on
due to their recent approv alfor the acute treatment of migraine. The half -lives of 
oral CGRP antagonists are in the range of 5 to 12 hours ,so a 14-day  washout 
period was considered appropriate to ensure a complete washout before a patient 
enters the study .
I5Q-MC-CGBC(a) Clinical Protocol Page 55
galcanezumab (LY2951742)Section # and Name [CONTACT_19523] 6.4 Screen 
FailuresExclusion Criterion [27] and [28] has been 
added to the statement, “Patients using a 
concomitant medication that requires a stable 
dose for a specific duration prior to Visit 1 
may be rescreened if additional time is needed 
to meet the duration requirement.”These Exclusion C riterio n were added so that patients may be rescreened if 
additional time is needed to meet the specific medication duration requirement.
Section 7.1 
Treatments 
AdministeredThe 140 mg/mL dose of erenumab has been
updated to 2 consecutive doses of 70 mg/mL 
each.This change was made to support the patient blinding so that each patient receiv es
2 injections.   This change also occurs in Section 7.1.1 (Packaging and Labeling ).
Section 7.2 Method of 
Treatment AssignmentStratification of randomization hasbeen
amended from migraine classification of 
epi[INVESTIGATOR_229487].Baseline migraine frequency was added ,as chronic migraine has been removed 
from the inclusion c riteria.  Since chronic migraine is excluded, it is expected that 
fewer patients will be on a concurrent migraine preventive treatment.  Therefore , 
migraine preventive treatment has been removed as a stratification factor.  BMI 
category (<30 kg/m 2, ≥30kg/m 2) was added to reduce any imbalance of outliers 
across the 2 treatment groups.   This change has also been made in Section [IP_ADDRESS] 
(Primary Analyses ).
The statement, “ The study treatment will be 
administered only once at Visit 3 after 
expulsion of the WMC has been confirmed” 
has been amended to “ The study treatment
will be administered only once at Visit 3.”Thisstatement was amended because administering the study treatment is not 
dependent on the expulsion of the WMC.
Section 7.3 Blinding This section has been amended to clarify that 
Study CGBC is now single blind.Additions were made to this section due to Study CGBC changing from an open -
label to a single -blind study so that the patient does not know treatment 
randomization .
Section 9.1. 1 Primary 
Assessment of GI 
Transit TimeThe statement, “Once enrolled into study, the 
patient will be asked to eat a SmartBar with 
120 mL water, followed by [CONTACT_229514] 50 mL of water” has been
amended to “Once enrolled into study, the 
patient w ill be asked to eat a SmartBar, 
followed by [CONTACT_229503] 120 mL 
of water.”This statement was amended due to a discrepancy with the SmartPi[INVESTIGATOR_229488].  The 
correction was made to align with the manual (Medtronic 2017).
I5Q-MC-CGBC(a) Clinical Protocol Page 56
galcanezumab (LY2951742)Section # and Name [CONTACT_19523] 9.2.1 Serious 
Adver se EventsThe statement , “Patients with a serious hepatic 
AE should have additional data collected 
using the eCRF ” has been removed .This statement was removed because hepatic lab oratory values are not being 
collected in this study .
Section [IP_ADDRESS] 
Suspec ted Unexpected 
Serious Adverse 
ReactionsThe statement, “ Suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) are serious 
events that are not listed in the IB and that the 
investigator identifies as related to study 
treatment or procedure ” has been amended to 
“Suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) are serious events that are 
not listed in the galcanezumab IB or the 
erenumab US package insert (USPI) and that 
the investigator identifies as related to study 
treatment or procedure .”This statement was amended to clarify what will be considered a S[LOCATION_003]R for both 
galcanezumab and erenumab .
I5Q-MC-CGBC(a) Clinical Protocol Page 57
galcanezumab (LY2951742)Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
“open-label ” is replaced by “ single- blind ” throughout the document and each 
instance is not identified with strikethrough/underscore.
Minor form atting and editorial changes have been made throughout the document 
and each instance is not ident ified with strikethrough/underscore.
Protocol I5Q -MC-CGBC
A Phase [ADDRESS_276241] 
WMC EvaluationNotes
Visit V1 V2 V3 V4 V5
Vital signsX X X XIncludes body temperature, sitting blood 
pressure, and pulse.
3.3. Benefit/Risk Assessment
Erenum ab is a human mo noclonal ant ibody that antagonizes the CGRP receptor.  The efficacy of 
erenumab for the prevent ion of migraine has been demonstrated in three Phase 3 rando mized, 
doubl e-blind trials (Goadsby  [CONTACT_2297] . 2017; Tepper et al. 2017; Dodick et al. 2018) .  Erenum ab [ADDRESS_276242] commo n adverse reactions (with an incidence of at least 2% for either 
dose of erenumab and at least 2% greater than placebo ) were inject ion site react ions, 
constipation , and cram ps/muscle spasms ( Aimo vig package insert, 2019; Ashina et al. 2019 ;
Aimo vig package insert, 2020 ).  Hy persensi tivity reactions , (including rash, angioedema, and 
anaphylaxis ), as well as const ipation with serious com plicat ions,and new- onset or worsening of 
pre-exist ing hypertensio nhave been reported with erenumab in postm arket ing experience.
I5Q-MC-CGBC(a) Clinical Protocol Page 58
galcanezumab (LY2951742)5.1. Overall Design
Abbreviations:  GI = gastrointestinal; LD = loading dose; Single -Blind = only the 
investigator, site personnel ,and sponsor will know the randomized treatment after 
randomization; SP = stud y period; TT WMC = wireless motility capsule transit time .
Figure CGBC. 5.1. Illustration of study design for Clinical Protocol I5Q-MC-CGBC .
Study Period II :  At the start of the single -blind open -label treatm ent peri od (Vi sit 3), pati ents 
will be rando mized in a 1:[ADDRESS_276243] ions of 70 mg each to achieve the 140 -mg 
dose.  At Vi sit 4, an addi tional WMC andrecorder will be given to patients fo llowing
calibrat ion.  Patients will exit the study  at Vi sit 5.
5.5. Justification for Dose
A galcane zumab 240- mg loading dose ( 2consecutive inject ions of 120 mg each) or a dose of 
140 mg erenumab ([ADDRESS_276244] ions of 70 mg each) will be administered by [CONTACT_229497] .
6.1. Inclusion Criteria
[2] Have a diagnosis of migraine (1.1 and 1.2 ICHD) , with or without aura , or 
chronic migraine , as determined by  [CONTACT_229515] S ociet y International Classificat ion of Headache 
Disorders –3rd edi tion guidelines (ICHD -3 2018).
[3] Have a frequency  of less than 15 m onthly headache day s of which up to 14 
can be migraine headache days.

I5Q-MC-CGBC(a) Clinical Protocol Page 59
galcanezumab (LY2951742)[43] Patients can be on no more than 1 other migraine prevent ive treatment (except 
for tricyclic ant idepressants and verapamil) as lo ng as: 
that pati ent has had a stable dose of the oral migraine preventive treatment for a 
minimum o f 2 months 
or
patients withchroni c migraine that have recevied onabotulinumtoxinA for  a 
minimum o f 2 cycles pri or to Vi sit 1.
6.2. Exclusion Criteria
[210] Patients wi th a body  mass index (BMI) of ≥50 40 kg/m2.
[276]Patients currently receiving a mAb CGRP antagonist on CGRP 
antag onists or have taken received a mAb CGRP antagonistwithin the past 6 
months prior to Vi sit 1.
[28] Have received an oral CGRP antagonist (gepant) 14 day s prior to Vi sit 1.
6.4. Screen Failures
Exclusio n criterion 27, 28, and 31:  Pati ents using a concomitant medication that 
requi res a stable dose for a specific duration prior to Visit 1 may  be rescreened if 
additional time is needed to meet the duration requirement.
7.1. Treatments A dministered
Table CGBC. 7.1. Treatment Regimens
RegimenDose
Day 7 ± 2
Galcanezumab 240 mg 240 mg
(2 120-mg SCinjection)
Erenumab 1 40 mg 140 mg
(21[ZIP_CODE] -mg SCinjection)
Abbreviation:  SC = subcutaneous.
7.2. Packaging and Labeling
Galcanezumab and erenumab will be supplied as an injectable solution in 1 -mL, single -dose, 
prefilled, disposable AI pen .Each AI pen of galcanezumab is designed to deliver 1 20 m g/mL, 
and each AI pen of erenumab is designed to deliver 140 70 mg/mL. All AI pens will be supplied 
insingle pen cartons, with the site to sel ect the appropri ate quant ity of AI pens, specific to the 
planned treatm ent schedule. Two g alcanezumab AI pens are needed for the galcanezumab (240 
mg)treatm ent.  One Two erenumab AI pen sareisneed edfor the erenu mab (140 m g) treatm ent.
I5Q-MC-CGBC(a) Clinical Protocol Page 60
galcanezumab (LY2951742)7.2. Method of Treatment A ssignment
To achieve between -group com parabilit y, the randomizat ion will be stratified by [CONTACT_3725], concurrent 
migraine prevent ive treatment BMI category (Yes/No <30kg/m 2, ≥30 kg/m 2), and by [CONTACT_229516] (<8 migraine headache days versus ≥8 migraine headache days) migraine 
classificat ion of epi[INVESTIGATOR_160348] .
7.2.1. Selection and Timing of Doses
The study  treatm entwill be administered only once at Visi t 3after expulsio n of the WMC has 
been confirmed.
7.3. Blinding
This is a nopen -label single -blind study .  Only the investigator, site personnel, and sponsor will 
know the rando mized treatment after randomizat ion.  Si te Personnel are responsible to ensure 
patients rem ain blinded to treatment (i.e., patients must not see the AI pens before, during, or 
after th e drug administration).  See the Manual o f Operati ons for further details regarding 
blinding.
9.1.1. Primary Assessment of GI Transit Time
The WMC (Medtronic 2017) measures who le gut and regional gut (stomach, small bowel, and 
colon) transi t times through measurement of pH, pressure, and temperature throughout the GI 
tract.  Once enro lled into study, the patient will be asked to eat a SmartBar with [ADDRESS_276245] for an addit ional 6 hours after the WMC is administered and wear an 
external data recorder for up to 5 day s. The WMC is a 4.5- g indigestible single -use, 27 12 mm 
cylindrical capsule.  Data are transferred to the accompanied wearable external  data recorder and 
displayed and analyzed using MotiliGI™ versio n 3.1 software (Medtronic 2017 ).
9.2.1. Serious A dverse Events
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within [ADDRESS_276246] addit ional data collected using the 
eCRF.
[IP_ADDRESS]. Suspected Unexpected Serious A dverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
inthe galcanezumab IB or the erenumab US package insert (USPI) and that the investigator 
ident ifies as related to study treatment or procedure.  [LOCATION_002] [ADDRESS_276247] ive 2001/20/EC and the associated detailed g uidances or nati onal 
regul atory  requi rements in partici pating countri es requi re the reporting of S[LOCATION_003]Rs.  Lilly has 
I5Q-MC-CGBC(a) Clinical Protocol Page 61
galcanezumab (LY2951742)procedures that will be fo llowed for the i dentification ,recording, and expedited reporting of 
S[LOCATION_003]Rs that are consistent with global regulat ions and the associated detailed guidances.
[IP_ADDRESS]. Primary Analyses
The primary  analysis will be performed using an analysis of covariance (ANCOVA) model.  The 
analysis will include the categorical effects of treatment and all rando mization stratificat ion 
factors (si te, co ncurrent use of migraine prevent ive treatment Yes vs No, and migraine 
classificat ion of epi[INVESTIGATOR_229489], and BMI categor y; see Section 
7.2), as well as the cont inuous baseline CTT.  Least squares mean change fro m baseline i n each 
treatm ent group will be tested to detect any  change in CTT between pre -and post -drug 
administration .
Appendix 1. Abbreviations and Definitions
Term Definition
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the treatment 
but the investigator and/his staff and the patient are not.
mAb monoclonal antibod ies
Leo Document ID = 98aeda5c-e244-43bf-a461-277a14f455da
Approver: 
Approval Date & Time: 19-May-2020 18:24:39 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 19-May-2020 19:42:40 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]